Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-04-16 Sale |
2024-04-17 6:42 pm |
ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner |
100,000 | $9.28 | $928,005 | 10,898,669 (Indirect Direct) |
View |
| 2024-04-16 Sale |
2024-04-17 6:40 pm |
ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner |
100,000 | $9.28 | $928,005 | 10,898,669 (Indirect Direct) |
View |
| 2024-04-09 Sale |
2024-04-10 5:39 pm |
ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner |
100,000 | $9.2773 | $927,735 | 10,999,622 (Indirect Direct) |
View |
| 2024-04-09 Sale |
2024-04-10 5:36 pm |
ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner |
100,000 | $9.2773 | $927,735 | 10,999,622 (Indirect Direct) |
View |
| 2024-03-25 Purchase |
2024-03-27 7:37 pm |
ARS Pharmaceuticals Inc. | SPRY | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner |
1,401,299 | $9.4836 | $13,289,410 | 10,860,977 (Indirect) |
View |
| 2024-03-22 Sale |
2024-03-26 6:48 pm |
ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner |
97,610 | $9.1212 | $890,322 | 11,048,669 (Indirect Direct) |
View |
| 2024-03-22 Sale |
2024-03-26 6:47 pm |
ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner |
97,610 | $9.1212 | $890,322 | 11,048,669 (Indirect Direct) |
View |
| 2024-03-19 Sale |
2024-03-21 9:51 pm |
ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner |
2,390 | $9.026 | $21,572 | 11,097,627 (Indirect Direct) |
View |
| 2024-03-19 Sale |
2024-03-21 9:50 pm |
ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner |
2,390 | $9.026 | $21,572 | 11,097,627 (Indirect Direct) |
View |
| 2024-03-13 Sale |
2024-03-15 7:55 pm |
ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner |
100,000 | $9.1368 | $913,681 | 11,149,622 (Indirect Direct) |
View |
| 2024-03-13 Sale |
2024-03-15 7:52 pm |
ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner |
100,000 | $9.1368 | $913,681 | 11,149,622 (Indirect Direct) |
View |
| 2024-02-29 Sale |
2024-03-01 8:21 pm |
ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner |
3,782 | $9.0165 | $34,101 | 9,151,123 (Indirect Direct) |
View |
| 2024-02-29 Sale |
2024-03-01 8:17 pm |
ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner |
3,782 | $9.0165 | $34,101 | 9,151,123 (Indirect Direct) |
View |
| 2024-02-26 Sale |
2024-02-28 9:08 pm |
ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner |
99,478 | $9.0208 | $897,368 | 9,152,123 (Indirect Direct) |
View |
| 2024-02-26 Sale |
2024-02-28 9:04 pm |
ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner |
99,478 | $9.0208 | $897,368 | 9,152,123 (Indirect Direct) |
View |
| 2023-09-28 Purchase |
2023-10-02 4:23 pm |
ARS Pharmaceuticals Inc. | SPRY | Fitzpatrick Alexander A Chief Legal Officer |
86,258 | $3.7093 | $319,954 | 89,227 (Direct) |
View |
| 2023-09-21 Purchase |
2023-09-25 4:30 pm |
ARS Pharmaceuticals Inc. | SPRY | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director |
2,700,000 | $3.0309 | $8,183,526 | 9,459,678 (Indirect) |
View |
| 2023-09-01 Sale |
2023-09-05 8:04 pm |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
100,000 | $7.7052 | $770,520 | 265,581 (Direct) |
View |
| 2023-08-29 Purchase |
2023-08-31 5:26 pm |
ARS Pharmaceuticals Inc. | SPRY | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director |
3,750,000 | $6.2 | $23,250,000 | 6,759,678 (Indirect) |
View |
| 2023-08-29 Purchase |
2023-08-31 5:26 pm |
ARS Pharmaceuticals Inc. | SPRY | ORBIMED ADVISORS LLC OrbiMed Capital GP VI LLC ORBIMED CAPITAL LLC Director |
500,000 | $6.2 | $3,100,000 | 9,240,887 (Indirect) |
View |
| 2023-08-29 Purchase |
2023-08-31 5:18 pm |
ARS Pharmaceuticals Inc. | SPRY | Thompson Peter A. Director |
500,000 | $6.2 | $3,100,000 | 9,240,887 (Indirect) |
View |
| 2023-08-03 Sale |
2023-08-07 5:05 pm |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
45,004 | $7.0325 | $316,489 | 235,237 (Direct) |
View |
| 2023-08-01 Sale |
2023-08-03 6:03 pm |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
54,996 | $7.1249 | $391,841 | 342,629 (Direct) |
View |
| 2023-07-07 Sale |
2023-07-07 8:16 pm |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
8,858 | $6.364 | $56,372 | 313,343 (Direct) |
View |
| 2023-07-03 Sale |
2023-07-06 8:55 pm |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
91,142 | $6.4784 | $590,453 | 644,043 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-01-02 Option Award |
2024-01-04 4:53 pm |
N/A 2034-01-01 |
ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E President and CEO 10% Owner |
1,180,000 | $0 | 10,952,522 (Direct) |
View |
| 2023-05-17 Gift |
2024-01-04 4:53 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E President and CEO 10% Owner |
1,050,000 | $0 | 10,952,522 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:47 pm |
N/A 2034-01-01 |
ARS Pharmaceuticals Inc. | SPRY | Karas Eric Chief Commercial Officer |
200,000 | $0 | 200,000 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:45 pm |
N/A 2034-01-01 |
ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina Chief Medical Officer 10% Owner |
1,180,000 | $0 | 10,102,554 (Direct) |
View |
| 2023-05-17 Gift |
2024-01-04 4:45 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina Chief Medical Officer 10% Owner |
1,050,000 | $0 | 10,102,554 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:42 pm |
N/A 2034-01-01 |
ARS Pharmaceuticals Inc. | SPRY | Dorsey Brian Chief Operating Officer |
350,000 | $0 | 350,000 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:41 pm |
N/A 2034-01-01 |
ARS Pharmaceuticals Inc. | SPRY | Chakma Justin Chief Business Officer |
350,000 | $0 | 350,000 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:39 pm |
N/A 2034-01-01 |
ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer |
200,000 | $0 | 200,000 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:38 pm |
N/A 2034-01-01 |
ARS Pharmaceuticals Inc. | SPRY | Fitzpatrick Alexander A Chief Legal Officer |
300,000 | $0 | 300,000 (Direct) |
View |
| 2023-09-01 Exercise |
2023-09-05 8:04 pm |
N/A 2030-04-28 |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
100,000 | $0 | 265,581 (Direct) |
View |
| 2023-09-01 Exercise |
2023-09-05 8:04 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
100,000 | $1.27 | 265,581 (Direct) |
View |
| 2023-08-03 Exercise |
2023-08-07 5:05 pm |
N/A 2030-04-28 |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
44,914 | $0 | 235,237 (Direct) |
View |
| 2023-08-03 Exercise |
2023-08-07 5:05 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
45,004 | $1.27 | 235,237 (Direct) |
View |
| 2023-08-01 Exercise |
2023-08-03 6:03 pm |
N/A 2030-04-28 |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
54,996 | $0 | 342,629 (Direct) |
View |
| 2023-08-01 Exercise |
2023-08-03 6:03 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
54,996 | $1.27 | 342,629 (Direct) |
View |
| 2023-07-07 Exercise |
2023-07-07 8:16 pm |
N/A 2030-04-28 |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
8,858 | $0 | 313,343 (Direct) |
View |
| 2023-07-07 Exercise |
2023-07-07 8:16 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
8,858 | $1.27 | 313,343 (Direct) |
View |
| 2023-07-03 Exercise |
2023-07-06 8:55 pm |
N/A 2030-04-28 |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
91,142 | $0 | 644,043 (Direct) |
View |
| 2023-07-03 Exercise |
2023-07-06 8:55 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
91,142 | $1.27 | 644,043 (Direct) |
View |
| 2023-06-27 Option Award |
2023-06-28 9:03 pm |
N/A 2033-06-26 |
ARS Pharmaceuticals Inc. | SPRY | Dadoo Rajeev Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-06-27 Option Award |
2023-06-28 9:00 pm |
N/A 2033-06-26 |
ARS Pharmaceuticals Inc. | SPRY | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director |
40,000 | $0 | 40,000 (Indirect) |
View |
| 2023-06-27 Option Award |
2023-06-28 9:00 pm |
N/A 2033-06-26 |
ARS Pharmaceuticals Inc. | SPRY | Kelly Michael Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-06-27 Option Award |
2023-06-28 9:00 pm |
N/A 2033-06-26 |
ARS Pharmaceuticals Inc. | SPRY | Shah Pratik Director 10% Owner |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-06-27 Option Award |
2023-06-28 9:00 pm |
N/A 2033-06-26 |
ARS Pharmaceuticals Inc. | SPRY | Thompson Peter A. Director 10% Owner |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-06-27 Option Award |
2023-06-28 9:00 pm |
N/A 2033-06-26 |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-06-27 Option Award |
2023-06-28 9:00 pm |
N/A 2033-06-26 |
ARS Pharmaceuticals Inc. | SPRY | SAUNDERS BRENT L Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-06-27 Option Award |
2023-06-28 9:00 pm |
N/A 2033-06-26 |
ARS Pharmaceuticals Inc. | SPRY | SCHNEIDER PHILLIP M Director |
40,000 | $0 | 40,000 (Direct) |
View |